Eastman's DOE Grant Is Back — and So Is a 2004-Style Propylene Arb

A reinstated grant cuts the circular capex bill, but Q4's unusual feedstock spread and a $560 million working-capital build are the real swing factors for 2027.

EMN · Earnings Call · 2026-10-30

The grant is back — but the scope is the real news

Eastman's quarter had one genuinely new company-specific item: the Department of Energy grant returned, and it returned with a different job. The old plan was a second methanolysis plant at Longview; the reinstated grant pulls in the debottlenecking of the existing Kingsport methanolysis plants, the feed-processing expansion in front of it, and the polymer/infrastructure needed to move more recycled product. The second plant is still in the scope, but it is now a smaller, more capital-efficient project because Eastman intends to reuse shuttered recycling and polymer assets rather than build everything greenfield. Costa was explicit that “the DOE will probably cover 30% to 50% of the capital cost associated with that combined investment” — Mark Costa, Board Chair and CEO · 2026-10-30. That is a meaningful change from January, when management said it was not spending engineering money until it had “a compelling project to be a lot more capital efficient” — Mark Costa, Board Chair and CEO · 2026-01-30. The grant has become that catalyst. But notice what happened to the narrative. The company's Circular Economy keyword lost altitude this quarter even as second-plant and methanolysis language rose. That fits the call: circular is no longer being sold primarily as a demand story that will rescue 2027. Revenue is tracking toward $100 million in 2026, with roughly $20 million of incremental earnings, and management called $100 million a minimum for 2027. Relative to a $2.5 billion quarterly revenue base, that is still a rounding item. The strategic value is now capital efficiency, customer validation and the option to build the second plant without stretching the balance sheet.

Q4: the Iran war trade flips into a war tax

The Iran war is the top company keyword this quarter, and the Iran conflict sits right behind it. For most of 2026, high oil and gas prices were a tailwind for a North American integrated chemical producer. In Q4, that trade has inverted in propylene. Costa laid out the anomaly:

Today, we're at $1.20 propane per gallon and $0.43 in PGP, and this is where it gets interesting. Asia, principally China is at $0.61 in the value of propylene. So you've got a $0.20 per pound arbitrage that's open between China and the U.S., and that is extremely unusual. In fact, the last time it was this big was in 2004, and it lasted about 2 months.
Mark Costa, Board Chair and CEO · 2026-10-30

The Q4 propylene-propane spread is around $0.14 versus $0.27 in Q3 and a 10-year average near $0.28. Management expects the arb to close, but not instantaneously because ships are constrained by the war. This is the main reason Q4 should not be annualized into 2027. It also explains why the company can sound constructive on next year while the quarter itself looks soft. Advanced Materials has its own version of the same problem. The PX spike tied to the conflict created about a $30 million full-year price-cost headwind, half of it in Q4. The commercial teams have already implemented increases, and Costa said “the January 1 price increases that we'll put in place will address that raw material cost challenge” — Mark Costa, Board Chair and CEO · 2026-10-30. If the war de-escalates and oil falls back into the $80s, that headwind flips into a 2027 tailwind.

Advanced Materials: innovation versus a 3% promise

Management still expects about 3% volume/mix growth in Advanced Materials for the full year, which implies a high-single-digit Q4 volume comparison. That is a lot to ask in a market where two-thirds of the segment serves discretionary end markets. The Q3 shortfall was not demand alone: a large Tritan line and a converted polymer line both started up about a month late. Costa was refreshingly specific: “we ran into some issues with some bad pumps that had to be replaced and delayed us by about a month” — Mark Costa, Board Chair and CEO · 2026-10-30. Both lines are now running, so Q4 does not carry the operational problem — but Q3 did, and it explains why volumes came in below the prior guide. The bigger issue is operating leverage. In the last filed quarter, total revenue was $2.5 billion, up 10% year over year, and operating income reached $256 million, up 51%. That sounds strong until you remember the base. The operating margin was 10.2%, against a 2013 peak of 20.0%. The company has spent years defending price and variable margin; what it has not had is volume. That is why every line start-up and every inventory swing matters so much.

Cash is the 2027 lever, and the arb is the risk

CFO Willie McLain cut the full-year operating cash flow guide to $850 million from $900 million, but the reason is timing and inflation, not deterioration. Working capital has built by $560 million year to date, largely raw materials for security of supply and the delayed turnaround. Inventory days have already come down from 115 at year-end 2025 to about 105. McLain expects release in Q4 and said “we think that's around $850 million, but that also sets us up for stronger cash in 2027” — William McLain, Executive Vice President and CFO · 2026-10-30. Even without another release, 2027 cash should exceed $850 million if the war does not re-escalate. Capex is the other half of the equation. Capital expenditure was $100 million in the last filed quarter, down 33% year over year, and management guides 2026 to about $400 million with a 2027 baseline near $500 million. The quiet upgrade is the ethylene-to-propylene metathesis project. In January it was pitched as “somewhere to $50 million to $100 million improvement in earnings and the payback on that is less than 2 years” — Mark Costa, Board Chair and CEO · 2026-01-30; now it is $75 million to $125 million, online in mid-2028, with a one-to-two-year payback and double the original scale. That project also reduces the earnings volatility from bulk ethylene sales, which is exactly what a specialty chemical investor wants to hear. Fibers is the other quiet confidence item. Management expects another mid-single-digit price decline in acetate tow in 2027 but better volume and asset utilization, enough to keep segment earnings stable. That is a more nuanced message than the prior calls, which were mostly about stabilizing volume. The proposed Jinan-Cerdia combination could be a stabilizing force if it leads to higher utilization rather than new capacity, though management wisely refused to predict customer behavior. The stock is not pricing a heroic recovery. Eastman is down 5.8% over the last 90 days and 11.5% from its August peak, and it remains 48.8% below its 2021 high. The DOE grant lowers the capital intensity of the circular platform, the E-to-P project is bigger than advertised, and working capital is a 2027 tailwind. But the Q4 propylene arb is a reminder that this is still a commodity-exposed specialty chemical company wearing a specialty multiple. Until the Iran war premium normalizes and the second plant moves from grant to steel, the cash release — not the circular narrative — is the most credible catalyst.